Novartis AG (LTS:0QM7) Cyclically Adjusted PS Ratio: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Novartis AG Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG  (LTS:0QM7) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novartis AG Cyclically Adjusted PS Ratio Related Terms


Novartis AG Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted PS Ratio Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.84 3.88 4.11 4.25 5.19

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.53 4.72 5.19 5.67 5.89

LTS:0QM7 vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.



Novartis AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.538/108.5600*108.5600
=5.538

Current CPI (Jun. 2026) = 108.5600.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.002 99.604 5.452
201612 5.368 99.380 5.864
201703 4.940 100.040 5.361
201706 5.097 100.285 5.518
201709 5.178 100.254 5.607
201712 2.692 100.213 2.916
201803 4.509 100.836 4.854
201806 4.918 101.435 5.263
201809 4.716 101.246 5.057
201812 5.041 100.906 5.423
201903 4.900 101.571 5.237
201906 5.092 102.044 5.417
201909 5.383 101.396 5.763
201912 5.416 101.063 5.818
202003 5.319 101.048 5.714
202006 4.799 100.743 5.171
202009 4.983 100.585 5.378
202012 5.068 100.241 5.489
202103 5.211 100.800 5.612
202106 5.345 101.352 5.725
202109 5.473 101.533 5.852
202112 1.885 101.776 2.011
202203 5.324 103.205 5.600
202206 5.742 104.783 5.949
202209 4.814 104.835 4.985
202212 4.734 104.666 4.910
202303 4.738 106.245 4.841
202306 4.900 106.576 4.991
202309 5.041 106.570 5.135
202312 4.719 106.461 4.812
202403 4.991 107.355 5.047
202406 5.331 107.991 5.359
202409 5.171 107.468 5.224
202412 5.602 107.128 5.677
202503 5.577 107.722 5.620
202506 5.591 108.075 5.616
202509 5.297 107.710 5.339
202512 5.118 107.200 5.183
202603 4.934 108.060 4.957
202606 5.538 108.560 5.538

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.